Amylin About
Amylin Pharmaceuticals: Amylin Pharmaceuticals, Inc.
is a biopharmaceutical company dedicated to developing innovative medicines to
improve the lives of people with metabolic diseases. The Company’s two late-stage,
first-in-class diabetes
product candidates are: –SYMLIN® (pramlintide acetate) and Exenatide
(synthetic exendin-4) Building on its experience in the diabetes field,
the Company is developing candidates for cardiovascular disease and obesity by
utilizing its research experience with the metabolic properties common to all
three conditions. SYMLIN is a synthetic version of
human amylin, a hormone secreted with insulin by the beta cells in the pancreas--
read more Exenatide
is a first-in-class drug candidate for the treatment of type 2 diabetes
read more Exentatide LAR -- a sustained release formulation of
exenatide, referred to as exenatide LAR. This development program utilizes Alkermes’
patented and proprietary Medisorb® injectable sustained release drug delivery
technology AC137 is in development for the potential treatment of
obesity. AC137 is pramlintide
acetate, the same compound as SYMLIN, Amylin’s lead drug candidate for type 1
and insulin-using type 2 diabetes- read
more.
More on Amylin
Pharmaceuticals
: